

AP20 Rec'd PCTPTO 04 MAY 2006  
MAILED/STOP PCT

Attorney Docket No. 27385U

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

TANAKA et al.

International Application No. PCT/JP2003/014243  
Serial No. NOT YET ASSIGNED

International Filing Date: 10 November 2003 (10.11.2003)

Filed: May 4, 2006For: INSULIN EXPRESSING HUMAN PANCREATIC ISLET CELL LINE CAPABLE  
OF REVERSIBLY PROLIFERATING AND USE THEREOFINFORMATION DISCLOSURE STATEMENTCommissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. § 1.97-1.98. Please note the following particulars:

[NOTE: One only of items a, b, c, and d must be checked.]

a. The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.

b. The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. § 1.113, or a notice of allowance under 37 C.F.R. § 1.311.

The enclosed statement is accompanied by [check one]:

i. a certification in part (e) below as specified in 37 C.F.R. § 1.97(e), or

ii. a check in the amount required by 37 C.F.R. § 1.17(p).

c. The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. § 1.113, or a notice of allowance under 37 C.F.R. § 1.311, but before payment of the issue fee.

Certification report(e) below; and

a check in the amount as required by § 1.17(p).

d. The enclosed statement is being filed pursuant to 37 C.F.R. § 1.97(i), for placement in the file.

e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /I.P./

AP2005CC0PC1PTO 04 MAY 2006

[  ] I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,  
or

[  ] I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

or

[  ] Appropriate certification is attached.

[  ] f. If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.

[  ] g. Copies of the documents are attached herewith with a completed Form PTO-1449.

And/or


[  ] h. Copies of the documents are not attached as allowed under 1.98(d)(1)(2). The earlier application is identified as:  
Or Copies of US Patents/Publications not attached as allowed in Official Gazette Aug. 5, 2003/ Vol. 1273, no. 1.

The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted,  
NATH & ASSOCIATES

By:



Gary M. Nath  
Registration No. 26,965  
Susanne M. Hopkins  
Registration No. 33,247  
Customer No. 20529

Date: May 4, 2006

NATH & ASSOCIATES PLLC  
112 South West Street  
Alexandria, VA 22314  
Phone: 703-548-6284  
Fax: 703-683-8396  
GMN/SMH/dd (IDS.revisedNov03)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /I.P./

10578260  
AP20 Rec'd PCT/PTO 04 MAY 2006

FORM PTO-1449		Atty. Docket 27385U	Serial No. Not yet assigned
		Applicant TANAKA et al.	
INFORMATION DISCLOSURE CITATION		Filing Date May , 2006	Group Art Unit Not yet assigned

## U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Issue Date	Name	Class	Sub-Class	Filing Date
	AA						
	AB						
	AC						
	AD						

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AE	1	SHIMON, E. "Cell replacement therapy for type 1 diabetes", <u>TRENDS in Molecular Medicine</u> , Vol. 8, No. 7, pp. 334-339 (2002).
	2	SALMON, P., et al. "Reversible Immortalization of Human Primary Cells by Lentivector-Mediated Transfer of Specific Genes", <u>Molecular Therapy</u> , Vol. 2, No.4, pp. 404-414 (October 2000).
AG	3	Halvorsen, T.L., et al. "Telomerase Activity Is Sufficient To Allow Transformed Cells To Escape from Crisis", <u>Molecular and Cellular Biology</u> , Vol. 19, No. 3, pp. 1864-1870, (March 1999).
	4	ZHU, J., et al. "Telomerase extends the lifespan of virus-transformed human cells without net telomere lengthening", <u>Proc. Natl. Acad. Sci.</u> , Vol. 96, pp. 3723-3728, (March 1999).
AI	5	WESTERMAN, K.A., et al. "Reversible immortalization of mammalian cells mediated by retroviral transfer and site-specific recombination", <u>Proc. Natl. Acad. Sci.</u> , vol. 93, pp. 8971-8976, (August 1996).
	6	O'HARE, M.J., et al. "Conditional immortalization of freshly isolated human mammary fibroblasts and endothelial cells" <u>Proc. Natl. Acad. Sci.</u> , vol. 98, no. 2, pp. 646-651, (January 16, 2001).
AK	7	DAVIES, B.R., et al. "Immortalisation of human ovarian surface epithelium with telomerase and temperature-sensitive SV40 large T antigen", <u>Experimental Cell Research</u> , vol. 288, pp. 390-402, (2003).
	8	KUDO, Y., et al. "Establishment of Human Cementifying Fibroma Cell Lines by Transfectin With Temperature-sensitive Simian Virus-40 T-antigen Gene and hTERT Gene", <u>Bone</u> , vol. 30, no. 5, pp. 712-717, (May 2002).
AM		
AN		
AO		
AN		

Examiner	/Ileana Popa/	Date Considered	06/04/2008
----------	---------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP ' 609.

Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to Office.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /I.P./